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Objectives 
One of the prognostic factors most 
highly associated with ovarian cancer 
survival is response to initial 
chemotherapy. Current prediction 
models of chemo-response built with 
comprehensive molecular datasets, like 
The Cancer Genome Atlas (TCGA), 
could be improved by including clinical 
and outcomes data designed to study 
response to treatment. The objective of 
this study was to create a prediction 
model of ovarian cancer chemo-
response using clinical-pathological 
features, and to compare its 
performance with a similar TCGA 
clinical model. 
Methods 
We first performed a retrospective case-
control study of 359 patients with 
primary, high-grade, advanced-stage 
serous ovarian cancer treated at a 
single academic institution. Responders 
were defined as those patients whose 
disease disappeared after standard 
chemotherapy and did not recur for 6 
months. Non-responders were defined 
as those with persistent disease or 
recurrence within 6 months of 
completing chemotherapy. A prediction 
model was created using a lasso (least 
absolute shrinkage and selection 
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operator) regression analysis and 
included clinical variables associated 
with chemo-response. Performance was 
evaluated using the area under the 
curve (AUC) of the receiver operating 
curve and its 95% confidence interval 
(CI). This prediction model was 
compared to a similar model derived 
using clinical variables available in 
TCGA dataset for serous ovarian 
cancer.  
Results 
As expected, the strongest predictor of 
survival in the single-institution cohort 
was chemo-response (p=2x10-16). 
Factors independently associated with 
chemo-response were age, grade, 
optimal surgery, residual disease after 
surgery, and receipt of neoadjuvant 
chemotherapy. The performance of the 
prediction model yielded an AUC of 0.72 
(95% CI of 0.69, 0.75). A similar clinical 
model from TCGA had an AUC of 0.53. 
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